Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Up 0.06% Nasdaq Down 0.01%
Streaming
Ticker Tape: On

More On TBGNF

Quotes

Charts

News & Info

Company

Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates
  • Research Reports

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials

  • Income Statement
  • Balance Sheet
  • Cash Flow

ThromboGenics NV (TBGNF)

-OTC Markets

43.50 Down 1.15(2.58%) May 24, 1:03PM EDT

Add to Portfolio
Prev Close:44.65
Open:43.90
Bid:N/A
Ask:N/A
1y Target Est:N/A
Beta:N/A
Next Earnings Date:N/A
Day's Range:43.45 - 43.90
52wk Range:24.60 - 62.40
Volume:2,475
Avg Vol (3m):2,777
Market Cap:1.56B
P/E (ttm):39.98
EPS (ttm):1.09
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in USD.

Headlines

  • No Headlines available for TBGNF at this time.

Reports

  • No Reports available for TBGNF at this time.

Key Statistics

Forward P/E (1 yr):N/A
P/S (ttm):16.47
Ex-Dividend Date:N/A

Analysts

Annual EPS Est () :N/A
Quarterly EPS Est () :N/A
Mean Recommendation*:N/A
PEG Ratio (5 yr expected):N/A

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

ThromboGenics, an integrated biopharmaceutical company, engages in developing and commercializing ophthalmic and oncology medicines in Belgium. It offers JET REA for the treatment of symptomatic vitreomacular traction. View More
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback